Hansa Biopharma Past Earnings Performance
Past criteria checks 0/6
Hansa Biopharma's earnings have been declining at an average annual rate of -18%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 55.3% per year.
Key information
-18.0%
Earnings growth rate
-11.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 55.3% |
| Return on equity | n/a |
| Net Margin | -345.7% |
| Next Earnings Update | 06 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hansa Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 189 | -655 | 355 | 376 |
| 30 Jun 24 | 164 | -802 | 397 | 398 |
| 31 Mar 24 | 166 | -845 | 438 | 422 |
| 31 Dec 23 | 134 | -832 | 450 | 411 |
| 30 Sep 23 | 114 | -856 | 428 | 395 |
| 30 Jun 23 | 159 | -759 | 400 | 390 |
| 31 Mar 23 | 148 | -678 | 361 | 368 |
| 31 Dec 22 | 155 | -611 | 338 | 346 |
| 30 Sep 22 | 139 | -626 | 357 | 322 |
| 30 Jun 22 | 77 | -620 | 357 | 292 |
| 31 Mar 22 | 55 | -583 | 348 | 254 |
| 31 Dec 21 | 34 | -548 | 327 | 231 |
| 30 Sep 21 | 22 | -491 | 287 | 213 |
| 30 Jun 21 | 18 | -465 | 256 | 224 |
| 31 Mar 21 | 14 | -431 | 224 | 222 |
| 31 Dec 20 | 6 | -421 | 203 | 227 |
| 30 Sep 20 | 3 | -426 | 193 | 234 |
| 30 Jun 20 | 3 | -398 | 187 | 210 |
| 31 Mar 20 | 3 | -381 | 177 | 203 |
| 31 Dec 19 | 3 | -360 | 167 | 193 |
| 30 Sep 19 | 4 | -330 | 150 | 178 |
| 30 Jun 19 | 3 | -298 | 128 | 167 |
| 31 Mar 19 | 4 | -274 | 104 | 166 |
| 31 Dec 18 | 3 | -248 | 90 | 155 |
| 30 Sep 18 | 3 | -216 | 68 | 148 |
| 30 Jun 18 | 3 | -192 | 54 | 142 |
| 31 Mar 18 | 3 | -178 | 49 | 132 |
| 31 Dec 17 | 3 | -177 | 44 | 137 |
| 30 Sep 17 | 3 | -161 | 39 | 126 |
| 30 Jun 17 | 3 | -151 | 37 | 115 |
| 31 Mar 17 | 3 | -136 | 35 | 104 |
| 31 Dec 16 | 3 | -111 | 30 | 83 |
| 30 Sep 16 | 4 | -97 | 26 | 73 |
| 30 Jun 16 | 3 | -84 | 24 | 62 |
| 31 Mar 16 | 3 | -76 | 27 | 51 |
| 31 Dec 15 | 7 | -66 | 28 | 44 |
| 30 Sep 15 | 5 | -60 | 26 | 36 |
| 30 Jun 15 | 5 | -51 | 22 | 32 |
| 31 Mar 15 | 4 | -34 | 7 | 31 |
| 31 Dec 14 | 2 | -29 | 8 | 22 |
| 30 Sep 14 | 2 | -21 | 13 | 14 |
| 30 Jun 14 | 3 | -20 | 18 | 10 |
| 31 Mar 14 | 3 | -19 | 24 | 0 |
| 31 Dec 13 | 2 | -18 | 19 | 0 |
Quality Earnings: 24H is currently unprofitable.
Growing Profit Margin: 24H is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 24H is unprofitable, and losses have increased over the past 5 years at a rate of 18% per year.
Accelerating Growth: Unable to compare 24H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 24H is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 24H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.